Two women discussing efruxifermin, or EFX, in front of a whiteboard

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Aug 2022 | From Akero Therapeutics

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis

Stephen A. Harrison, Peter J. Ruane, Bradley Freilich, Guy Neff, Rashmee Patil, Cynthia Behling, Chen Hu, Reshma Shringarpure, Brittany de Temple, Erica Fong, Erik J. Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale JHEP Reports

Nov 2021 | From Akero Therapeutics

Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats

Tillman, E. Et al. The British Journal of Pharmacology

Jul 2021 | FROM AKERO THERAPEUTICS

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Harrison, S. et al. Nature Medicine

Dec 2020 | From Akero Therapeutics

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

Tillman, E., and Rolph, T. Frontiers in Endocrinology

Jul 2020 | FROM AKERO THERAPEUTICS

AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients

Kaufman, A. et al. Cell Reports Medicine

Dec 2019 | FROM EXTERNAL EXPERTS

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Sanyal, A. et al. Lancet

Aug 2018 | FROM EXTERNAL EXPERTS

A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway

Bao, L. et al. British Journal of Pharmacology

Jul 2018 | FROM EXTERNAL EXPERTS

A systematic dissection of sequence elements determining β-Klotho and FGF interaction and signaling

Shi, S.Y. et al. Scientific Reports

Close up of multichannel micropipette filling four small blue centrifuge tubes

We have developed a comprehensive clinical program to evaluate EFX as a potential treatment for MASH.

View Our Pipeline